Chicago, IL: The administration of nabilone – a synthetic THC analog marketed in the United States under the brand name Cesamet – reduces agitation and other behavioral symptoms in Alzheimer’s patients, according to the results of placebo-controlled clinical trial data presented at the Alzheimer’s Association 2018 International Conference.
Researchers from the University of Toronto reported that the oral administration of nabilone capsules significantly improved patients’ symptoms compared to placebo over a 14-week randomized trial. Investigators also documented improvements in patients’ cognition and nutrition.
Cesamet is FDA-approved to treat nausea and vomiting in patients undergoing cancer chemotherapy.
Separate clinical trials have previously reported similar results associated with the use of the oral THC drug dronabinol.
For more information, contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org.